Barbara Weber, M.D., has been the CEO of Tango Therapeutics since March 2017. With an M.D. from a top medical school, her background is solid in medicine, specifically in oncology and drug development. Before Tango, she held significant roles at...

Barbara Weber, M.D., has been the CEO of Tango Therapeutics since March 2017. With an M.D. from a top medical school, her background is solid in medicine, specifically in oncology and drug development. Before Tango, she held significant roles at major pharmaceutical companies like Novartis and GlaxoSmithKline, where she was part of teams that pushed boundaries in cancer research. Under her leadership, Tango has focused on developing novel cancer treatments using innovative approaches like synthetic lethality. Dr. Weber's vision is clear: tackle the genetic complexities of cancer to improve patient lives. Her management style has led to key advancements in the company’s clinical trials and a strong research team. In 2023, her total compensation was about $3.4 million, including a performance-based bonus reflecting the company's achievements. Interestingly, she is a Venture Partner at Third Rock Ventures, which suggests her insights in biotech extend beyond her CEO role. Known for her hands-on approach, she actively monitors performance metrics to align company goals with employee incentives. Her insider trading activity shows a mix of buying and selling stocks, indicating strategic financial management. Dr. Weber is not just leading a company; she's on a mission to change how we understand and treat cancer. Her strategy combines science, leadership, and a commitment to innovation, shaping the future of healthcare.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

T

Barbara Weber, M.D.

CEO of Tango Therapeutics

Education

B.S. in Chemistry and an M.D. from the University of Washington

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

CEO of Tango Therapeutics for

8 years 3 months (Mar 2017 - Present)

Previous Experience

Senior Vice President, Oncology Translational Medicine, Novartis; Vice President, Oncology, GSK; Professor, Medicine and Genetics, University of Pennsylvania

Rivals

Competitors/colleagues of Barbara Weber, M.D.

Holdings

See how much did Barbara Weber, M.D. make over time.

Dr. Barbara Weber's insider stock trading activity reveals a pattern of strategic financial decisions. In June 2023, she executed a notable sale worth approximately $6.69 million, showcasing her confidence in Tango's trajectory. Her holdings peaked notably earlier in 2023, particularly...

Dr. Barbara Weber's insider stock trading activity reveals a pattern of strategic financial decisions. In June 2023, she executed a notable sale worth approximately $6.69 million, showcasing her confidence in Tango's trajectory. Her holdings peaked notably earlier in 2023, particularly around August, when her trades surpassed $9 million. This was likely influenced by significant developments in the company's clinical trials and advancements in drug discovery. The fluctuations in her stock activity highlight not only her active role in corporate governance but also an effort to balance personal investment risks with the company's growing value. As of December 2023, her market value in Tango stock reflects a considerable portion of her wealth, cementing her belief in the company's mission and future prospects.

Total Stock Sold

$116.28K

TNGX

$116.28K

9,138 TNGX shares

What if they kept their stock?

If Barbara Weber, M.D. didn't sell their stock, today they would have:
Extra TNGX9,138 shares worth $91.29K.
This is -21.49% and $24.99K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Barbara Weber, M.D..

TNGX

$115.06K

TNGX at $12.59/share

Feb 6, 2024

Sale

TNGX

87,168 shares

TNGX

Feb 1, 2024

Received

TNGX

89,545 shares

TNGX

Mar 1, 2023

Received

Compensation History

See how much did Barbara Weber, M.D. make over time.

In 2023, Barbara Weber, M.D., earned a total compensation of $3,391,059 as CEO of Tango Therapeutics. This included a base salary of $625,997, a bonus of $396,576 based on surpassing company performance goals, and significant long-term incentives in the form of stock options valued at approximately $1.88 million. Her compensation structure is designed to align her interests with the company's performance, emphasizing the importance of sustenance in innovative drug development and clinical trials. The bonus payout reflected a hit rate of 115% of the target, showcasing not just individual drive but also the collective success of Tango’s operational goals. In previous years, her compensation peaked in 2021 at over $11 million, driven mainly by options grants during a significant growth phase for the company.

Year

2023

Total Compensation

$1.04M

Salary

$626.00K

Board Justification

The compensation philosophy is designed to attract and retain top talent while aligning executive compensation with company performance and shareholder interests.

Bonus

$396.58K

Board Justification

The bonus for 2023 was based on achieving corporate performance metrics, resulting in a payout of 115% of the target bonus.

Other

$17.24K

Board Justification

Other compensation includes $13,200 of matching contributions under the 401(k) plan, $2,100 of commuter benefits, and $1,300 for phone services paid by the company.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was reported as vested in 2023; only stock grants and options are included in the total compensation calculations.

Performance Metrics

Performance metrics for 2023 included research and development advances, operational and strategic metrics, and individual contributions.